Argenx Shares up as Much as 7.2% After Disappointing Study From Rival Biohaven's Protein-Degrader Drug - Traders
在競爭對手Biohaven的蛋白質降解劑藥物令人失望的研究之後,Argenx股價上漲了7.2%——交易者
Argenx Shares up as Much as 7.2% After Disappointing Study From Rival Biohaven's Protein-Degrader Drug - Traders
在競爭對手Biohaven的蛋白質降解劑藥物令人失望的研究之後,Argenx股價上漲了7.2%——交易者
譯文內容由第三人軟體翻譯。